Adlai Nortye Pharmaceutical Co. Ltd. has described molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degraders reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.

The Dana-Farber Cancer Institute has identified molecular glue degraders comprising a cereblon (CRBN) ubiquitin ligase-binding moiety covalently bound to a zinc finger protein Helios (IKZF2) ligand reported to be useful for the treatment of cancer.